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Adipose Stromal Cells Improve Healing of Vocal Fold Scar:
Morphological and Functional Evidences
Guillaume de Bonnecaze, MD; Benoit Chaput, MD; Virginie Woisard, MD, PhD;
Emmanuelle Uro-Coste, MD, PhD; Pascal Swider, PhD; Sebastien Vergez, MD, PhD; Elie Serrano, MD;
Louis Casteilla, PhD; Valerie Planat-Benard, PhD
Objectives/Hypothesis: Adipose derived stromal cells (ASCs) are abundant and easy to prepare. Such cells may be use-
ful for treating severe vocal disturbance caused by acute vocal fold scars.
Study Design: Prospective animal experiments with controls.
Methods: Twenty New-Zealand white rabbits were used in the present study. We evaluated vocal fold healing, with or
without injection of autologous ASCs, after acute scarring. A defined lesion was created and the ASCs were immediately
injected. Vocal fold regeneration was evaluated histomorphometrically and via viscoelastic analysis using an electrodynamic
shaker.
Results: Six weeks after ASC injection, vocal folds exhibited significantly less inflammation than control folds (P < 0.005).
In addition, hypertrophy of the lamina propria and fibrosis were significantly reduced upon ASC injection (P < 0.02). The
decrease in viscoelastic parameters was less important in the ASC injected group compared to the noninjected group (P 5 0.08).
Conclusion: Injection of autologous ASCs improved vocal fold healing in our preclinical model. Further studies are
needed, but this method may be useful in humans.
Key Words: Wound healing, cytotherapy, vocal fold scar, adipose stromal cells, biomechanical analysis.
Level of Evidence: NA.
INTRODUCTION
Scarring caused by trauma, radiation, infection, or
inflammation is a common cause of severe vocal disturb-
ance. Current treatment features surgery and rehabilita-
tion, with several associated problems including a
requirement for general anesthesia, delivery of new
insults to tissue, fibrotic deterioration and relapse. Sev-
eral recent studies1–4 have shown that injection of multi-
potent stem cells improved wound healing in preclinical
models. Stem cell transplantation is an attractive
approach that complements traditional restorative or
surgical techniques seeking to regenerate injured or
pathologically damaged laryngeal tissues. However, to
date no optimal cell delivery strategy has been
identified.
We developed a new approach in which adipose-
derived stromal cells (ASCs) containing multipotent cells
of adipose tissue were used to heal injured vocal folds.
Adipose-derived stromal cells have been studied in the
context of cell differentiation,5,6 tissue engineering,7–9
and immunomodulation.10,11 From the perspective of the
ear, nose, and throat (ENT) specialist, such cells have two
very interesting characteristics: they are abundant and
easy to prepare. In addition few recent evidences
suggested the interest of ASCs in vocal fold wound
healing. Adipose-derived stromal cells have demonstrated
their antifibrotic properties in vitro.12,13 Recently others
studies showed that ASCs could induce favorable remodel-
ing of scarred vocal folds in vivo by their interactions with
endogenous fibroblasts.14 Thus, we developed a preclinical
cell therapy model in which autologous ASCs were
injected after acute vocal fold scarring in rabbits. We then
analyzed the effect of ASCs on lamina propria morphology
and residual inflammation during the healing process. We
also developed a novel method to assess the dynamic of
the viscoelasticity property of the vocal fold.
MATERIALS AND METHODS
Experimental Animals
Twenty New Zealand white rabbits (2.8–3.1 kg) were used in
the present study. The animals were housed in a controlled environ-
ment (a 12-hour light/dark cycle at 218C) with free access to water
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and a standard chow diet. Our institutional ethics committee
approved all of the procedures; the committee considered that we
had minimized the number of animals to be used, as well as their
pain.
Surgical Procedure
Before surgery, each rabbit received intramuscular injec-
tions of Calmivet (5 mg/mL, 0.1 mL/kg; Vetoquinol, Lure Cedex,
France), ketamine (50 mg/mL), and Rompun (2% weight/volume
[w/v] xylazine) (0.25 mL/kg; Bayer Healthcare, Leverkusen,
Germany). In the first surgical procedure, 1 g of subcutaneous
fat was collected and immediately placed in phosphate-buffered
saline (PBS) (Dulbecco, New-York, United States of America.).
Fifteen days later, the ASCs were dispersed with trypsin (Gibco,
Saint Aubin, France), and after counting (Beckman Coulter,
California, United States of America.) were diluted to 2 3 106
cells/0.2 mL PBS. On this day, all of the animals underwent
their second surgical procedure under general anesthesia; the
left-side vocal fold was scarred via calibrated electro cauteriza-
tion. The animals were then separated into two groups, and all
of the rabbits in the test group were immediately injected with
autologous ASCs; controls received 0.9% (w/v) saline. The exper-
imental protocol is summarized in Figure 1.
We performed cervicotomy with a median cricolaryngec-
tomy (Fig. 2). A midline incision from the crico thyroid mem-
brane to the thyroid cartilage was then made to view the vocal
folds. In preliminary work, we determined that 40 milliamperes
(mA) electrocoagulation delivered over 1 second scarred all
three layers of the vocal fold: the epithelium, Reinke’s space,
and the thyroarytenoid muscle. All of the operations were on
the left side; the right side served as unscarred controls. The
Fig. 1. Experimental protocol.
full length of the vocal fold was scarred with the same intensity
(40 mA). All of the injuries were performed in the same condi-
tion. Finally, the median thyroidotomy was closed.
Immediately after electrocoagulation, 14 left-side vocal folds
were injected with 2 3 106 ASCs in 0.1 mL saline solution, and
six folds were injected with 0.1 mL saline solution only. All of the
injections were into the lamina propria using a 19-gauge needle.
All of the animals survived the procedure. We monitored
their general status, well-being, appetite, and weight. No ani-
mals lost weight and no side effects of the ASCs injection were
noted. After 6 weeks, all of the animals were painlessly sacri-
ficed by intravenous injection of an overdose of sodium pento-
barbital (54 mg/mL, 100 mg/kg; Ceva Sante, Libourne, France)
under general anesthesia. The larynges were dissected out, and
each larynx was divided at the sagittal midline. Seven left hem-
ilarynges (four injected with ASCs, and three injected with
saline) were immediately snap-frozen at –208C prior to visco-
elastic analysis. In total, 13 hemilarynges (10 injected with
ASCs; 3 injected with saline) were placed in 4% (volume/volume
[v/v]) formaldehyde prior to histological analysis.
Preparation of Adipose-Derived Stromal Cells
Subcutaneous inguinal adipose tissue was digested at 378C
in PBS containing 2% bovine serum albumin and 2 mg/mL colla-
genase (Serva, Eidelberg, Germany) for 35 minutes. After elimi-
nation by filtration through 25-lm filters of undigested
fragments, floating mature adipocytes were separated from the
pellet-containing cells from the stromal vascular fraction by cen-
trifugation (600 g, 10 minutes). Stromal-vascular fraction cells
were plated (4,000 cells/cm2) in Dulbecco’s Modified Eagle
Medium (DMEM): Nutrient Mixture F-12 containing 10% new-
born calf serum and supplemented with amphotericin 0.25 lg/
mL, streptomycin 0.1 mg/mL, and penicillin 100 U/mL (all Life-
Technologies, Saint Aubin, France). At subconfluence, ASCs were
passaged using trypsin-EDTA (ethylenediaminetetraacetic acid;
LifeTechnologies) and cultured until use at passage P1. We con-
firmed that the adherent cells obtained had the conventional phe-
notypic signature of ASCs (CD341, CD452, CD312, CD731, and
CD901), as well as their in vitro characteristics (clonogenic activ-
ity using the colony-forming unit-fibroblast assay, differentiation
potential into adipocytes and osteoblasts), as described by Zuk
et al.5
Tissue Staining
Vocal folds removed from hemilarynges were further proc-
essed in 4% (v/v) paraformaldehyde, rinsed in 10% (w/v) sucrose,
dehydrated in a graded series of ethanol baths, embedded in paraf-
fin wax, and cut into 5-lm thick frontal (coronal) sections. The
stains used were hematoxylin & eosin (H&E), picrosirius (to detect
fibrosis), and orcein (to detect elastic fibers). We studied a 2-mm
thick region in the middle of each vocal fold. We stained 10 slices
with H&E (a slice every 200 lm), and five slices with picrosirius
and orcein (a slice every 400 lm). On the H&E-stained slides, we
measured the thicknesses of the epithelium and the lamina prop-
ria and calculated the average values (NIS-Elements 3.0, Nikon
Inc., Melville, NY; 10 measurements on each of 10 samples). We
assessed the extent of inflammation in each vocal fold. The Chis-
holm classification,15 derived to assess inflammation in salivary
gland disease, was used to identify inflammatory foci, defined by
colocalization of at least 50 immunocompetent cells (plasmocytes,
macrophages, and/or histiocytes) (Fig 3). We evaluated the extent
of fibrosis on the picrosirius-stained slides by calculating the aver-
age thickness of fibrosis within the lamina propria. We also studied
the mean optical density analysis in 10 sections of picrosirius
staining. The integrated optical density (IOD) was evaluated by
Fig. 2. Surgical procedure. After median laryngotomy, the left vocal
fold was electro cauterized, and immediately injected with adipose
tissue-derived stromal cells or saline (single arrow: vocal fold; dou-
ble arrow: arytenoid cartilage).
Fig. 3. Inflammatory foci (1003 and 4003 magnification) with a dotted circle around it (A). Each focus contains at least 50 inflammatory
cells (B).
NIS-Elements 3.0 (Nikon Inc.). Orcein staining revealed the den-
sity of elastic fibers (fibers/5,000 lm2; NIS-Elements 3.0, Nikon
Inc.) and their organization. An experienced cytopathologist,
blinded to the treatment, performed all of the histological
analyses.
Immunohistochemistry
Paraffin-embedded sections were deparaffinized in xylene
and dehydrated in ethanol. Blocking (1 hour) was performed in
PBS. Slides were incubated with primary mouse monoclonal
antibodies against collagen type 1 (clone C2456; Sigma-Aldrich,
St. Louis, MO) or fibronectin (Sigma-Aldrich clone F0791); the
levels of both proteins increased in pathological situations.16–19
Antibody fixation was detected by addition of 200-lL diethyla-
minoazobenzene. We studied the localization, organization, and
density of the two proteins using a semiquantitative analysis
performed by a trained specialist.
Persistence of Transplanted ASCs
In order to follow the presence of ASCs after administra-
tion in vocal focal folds, two additional rabbits were injected
with ASCs expressing enhanced-green fluorescent protein
(EGFP). Briefly, ASCs in primary culture were transduced over-
night using a lentiviral vector (BiviC core vector facility,
IFR 150, Toulouse, France) in a transduction medium contain-
ing serum-free medium, 15% BIT9500 (Stemcell Technologies,
Grenoble, France), and 4lg/mL Protamine Choay (Sanofi-Aven-
tis France, Paris, France) in the presence of purified lentiviral
vectors at multiplicity of infection 50. Cells were collected
72hours after transduction for EGFP-positive cells quantifica-
tion by flow cytometry analysis on a fluorescent-activated cell
sorter (FACS Canto II, Becton Dickinson, Mountain View, CA).
Injected EGFP expressing ASCs were detected immunohisto-
chemically using an anti-GFP antibody (Abcam, Cambridge,
U.K.) in 20 tissue sections from each vocal fold.
Biomechanical Measurements (Using an
Electrodynamic Shaker)
We used modal analysis to measure the viscoelastic proper-
ties of vocal folds. As shown in Figure 4, each vocal fold was
clamped between two rigid blocks of polyethylene, forming a
cylindrical structure with a point mass at the center. A hole was
created at r2 5 1.5 mm 6 1% in the center of the specimen. The
implant and fixture masses were 1.53 3 10–4 kg 6 0.5% and 0.4
kg 6 0.1%, respectively. The average mass of the tissue sur-
rounding the implant was 3.32 3 10–4 kg 6 1%, which was esti-
mated by averaging the specimen weights in a companion
study20 after destructive static pushout testing. We measured the
first natural frequency, x1, associated with the symmetric mode
shape /; this was the maximum displacement of the central
region of the vocal fold. To generate base excitation, the fixture
was mounted on an electrodynamic shaker (Gearing & Watson,
Hailsham, East Sussex, U.K.) fitted with a piezoelectric force
gauge (8200 Br€uel & Kjaer, Nærum, Denmark). An attached
eddy current sensor (TQ102 Vibrometer, Meggit SA, Fribourg,
Switzerland) allowed the relative displacement xr of the central
titanium region to be measured. The base displacement x0 was
monitored upon imposition of a swept sine wave in the range 20
Hz to 2.5 kHz. The frequency response function, Xr/F (X), was
computed by Dynamic Signal and System Analyzer (Siglab; Spec-
tral Dynamics, San Jose, CA). Here, the greatest value of X rep-
resents the first natural frequency x1; this frequency is
characteristic of the biomechanical properties of a vibrating tis-
sue and is correlated with the tissue k value; thus: k 5 x1
2
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weight (kg). The reliability of the method and the capacity
thereof to detect pathological changes have been described.21
Statistical Analysis
All of the values were expressed as means with standard devi-
ations. A P value < 0.05 was considered statistically significant.
Nonparametric comparisons between groups were made using Stu-
dent’s t test. We used the Mann-Whitney test (GraphPad Prism 5,
GraphPad Software, San Diego, CA) to compare dynamic data.
RESULTS
Histology
We measured the epithelial and lamina propria thick-
nesses on 10 samples from each rabbit (7 scarred ASCs-
injected vocal folds; 4 scarred saline-injected vocal folds; 3
untreated controls). The mean of epithelial thickness of
nonscarred vocal folds was 60 lm (55–71 lm) versus 52 lm
(47–60 lm) in the scarred vocal folds injected with ASCs,
and was 45 lm (37–60 lm) in the noninjected scarred vocal
folds (P < 0.02). The mean of lamina propria thickness of
the nonscarred vocal folds was 130 lm (112–157 lm) ver-
sus 279 lm (152–369 lm) in the scarred vocal folds injected
with ASCs, and was 510 lm (412–589 lm) in the nonin-
jected scarred vocal folds (P < 0.002) (Fig. 5). Sirius red
staining showed that the thicker folds exhibited higher lev-
els of fibrosis. The optical density analysis showed that the
IOD of vocal folds treated with ADSC was significantly
lower than vocal folds treated with saline (P < 0.01) (Supp.
File S1).
Orcein staining showed that scarring reduced the
density of elastic fibers, ASCs injection significantly
inhibited this decrease (nonscarred group: 82 fibers/
5,000 lm2; scarred ASCs-injected group: 40.3 fibers/
5,000 lm2; scarred noninjected group: 19.7 fibers/5,000
Fig. 4. The two degrees of freedom system. The experimental
device is shown. The eddy current sensor measures the trans-
verse displacement (32–31) of the vocal fold.
lm; P < 0.001). The extent of inflammation was higher
in the scarred untreated group than the ASC-treated
scarred group. The ASCs-treated scarred vocal folds had
0.8 (0–2) inflammatory foci/mm3 in contrast to the 3.5
foci (1–4) inflammatory foci/mm3 on saline-injected
scarred vocal folds (P < 0.005).
Immunohistochemistry
In normal vocal folds, collagen type I was essen-
tially confined to the upper region of the lamina propria
(Fig. 6). After scarring, the protein content decreased in
this region but increased in the lower region in a disor-
ganized manner. In the ASCs-injected group, collagen
1A levels decreased in the upper region of the lamina
propria but did not accumulate in the lower region. The
fibronectin labeling showed that the level of this protein
was increased after scarring within the lamina propria.
Adipose-derived stromal cells seemed to have no signifi-
cant effect on this modification. Neither the density nor
the organization of fibronectin varied between ASCs-
injected and noninjected groups.
Fig. 6. Anti-collagen 1 immunohistochemistry magnification 1003: nonscarred (left), ASC noninjected (middle), and ASC-injected scarred (right)
vocal fold. ASC5 adipose-derived stromal cells.
Fig. 5. Thickness of the lamina propria and epithelium. ASC limited lamina propria hypertrophy and epithelium atrophy 6 weeks after scar-
ring. ASC 5 adipose-derived stromal cells; E 5 epithelium; LP 5 lamina propia.
Persistence of Transplanted Adipose-Derived
Stromal Cells
After 21 days, most samples were negative for GFP-
expressing cells, suggesting that ASCs were only transi-
ently present (data not shown). Unspecific GFP labeling
was observed in some epithelial (and adjacent endothe-
lial) cells. No muscle or mesenchymal cells were found
GFP-positive, showing that ASCs did not transdifferenti-
ate into such cell types.
Biomechanical Data
Six weeks after scarring, the biomechanical proper-
ties of the vocal folds were measured. The first natural
frequency and the X/F ratio decreased in noninjected
scarred compared to control vocal folds (P 5 0.03).
Adipose-derived stromal cells mitigated the reduction of
the first natural frequency in scarred vocal fold com-
pared to noninjected scarred vocal fold (P 5 0.08) (Fig.
7). The mean of the first natural frequency of the normal
vocal folds was 212 Hz (194–236 Hz) but was 120 Hz
(110–125 Hz) in ASCs-injected vocal folds and 100 Hz
(98–111 Hz) in scarred noninjected vocal folds, suggest-
ing that ASCs might limit biomechanical changes of the
vocal fold after scarring.
DISCUSSION
Over the last decade, it has become clear that stem
cell therapy was probably the most promising treatment
for severe vocal disturbance that develops after vocal
fold scarring. Various stem cells (mesenchymal stem
cells [MSCs], bone marrow-derived stem cells [bMSCs],
and human embryonic stem cells [hESCs]) have been
used in different preclinical models. Most models were
performed using allogenic transplantation of cells accom-
panied by immunosuppression. Kanemaru et al.1,2
showed that bMSCs assisted regeneration of scarred
vocal folds in a nude rat model 8 weeks after injection.
More recently, the same group showed that dogs injected
with autologous bMSCs enjoyed faster functional recov-
ery than animals treated with autologous induced-
muscle progenitor cells. Herteg€ard et al.3 applied human
mesenchymal stem cells (hMSCs) to a rabbit model,
demonstrating that the cells seemed to improve vocal
fold wound healing. More recently, Svensson et al.22
found a significant reduction in lamina propria thickness
after injection of hMSCs. Cedervall et al.4 used hESCs
in a rabbit model and reported that the cells improved
the biomechanical properties of the vocal fold. However,
from the viewpoint of the ENT surgeon, the clinical use
of hESCs requires additional robust safety data and is
limited by ethical concerns.
Adipose tissue was long considered inert and unat-
tractive. However, over the past 20 years, it has become
recognized that mesenchymal cells of this tissue exhibit
beneficial trophic effect and the ability to support tissue
regeneration and functional recovery after an initial
lesion.23 In addition, this tissue is an abundant source of
MSCs, which can be easily removed under local anesthe-
sia, dispersed, and percutaneously injected into a
scarred vocal fold. Only few studies have already
explored the use of ASCs to manage acute or chronic
vocal fold scarring,12–14 mainly with nonautologous cells.
We sought to develop a preclinical model of ASCs ther-
apy to treat acute vocal fold scarring without the need
for immunosuppression.
We found that ASCs improved vocal fold wound
healing. Our data are in accordance with Herteg€ard3
and Rousseau,16–24 who showed that vocal fold scarring
increased lamina propria thickness, which is principally
caused by increased fibrosis. We obtained that ASCs
injected immediately after scarring reduced hypertrophy
and fibrosis. Similar results have recently
appeared.9,25–27 We evaluated all of the 16 injected ani-
mals and revealed that in two treated rabbits, the lam-
ina propria thickness was near-normal (157 lm vs. 130
lm). Similar results have recently been reported.9,12 The
antifibrotic properties of ASCs have also been demon-
strated in vitro. Kumai et al.12,13 sought to modulate the
activities of fibroblasts within vocal fold scars and found
that ASCs changed the secretion profile of the resident
fibroblasts. They showed that in the presence of ASCs
collagen secretion fell, the fibroblasts proliferated and
synthesis of hepatocyte growth factor (HGF) and hyal-
uronic acid increased. Fibroblasts regulate synthesis of
the extracellular matrix compounds in response to para-
crine or mechanical stimuli.17,18 Thus, ASCs may exert a
paracrine-like effect on resident fibroblasts, probably by
mediating the synthesis of HGF, fibroblast growth factor
2, TGF-b, or MMP9–1. Indeed Hiwatashi et al14 demon-
strated that the synthesis of HGF; FGF2; and hyalur-
onan synthase 1, 2, and 3 was upregulated in the ASCs
group.
Residual inflammation is one of the most common
causes of surgical failure; all of the surgical procedures
are aggressive and trigger local inflammation. Mesen-
chymal stem cells exhibited immunomodulatory effects
and injection of such cells can control graft-versus-host
disease10; MSCs also inhibited immune cell proliferation
in vitro.11 In the present study, we found it difficult to
measure residual vocal fold inflammation after 6 weeks.
We performed blinded semiquantitative histological
assessment and suggested that ASCs significantly
Fig. 7. The first natural frequency decreased 6 weeks after scar-
ring. ASCs tended to normalize biomechanical properties. ASC 5
adipose-derived stromal cells.
limited inflammation. Further studies on the role of
ASCs in proinflammatory cytokine production—includ-
ing IL-1, IL-6, and TNFa—are still required. However,
the decrease in inflammatory cell numbers in ASCs-
injected scarred vocal folds is encouraging.
Scarring and stiffness of vocal folds have previously
been attributed to an increase in the collagen content of
the lamina propria.16,24 Preliminary studies showed that
MSCs injection significantly reduced the level of collagen
type I,3 but more recently Cedervall et al.4 found other-
wise. We confirmed that collagen type I was located in
the upper part of the lamina propria,16 and that scarring
increased the level thereof and rendered the collagen
structure disorganized, especially in the lower part of
the lamina propria. Adipose-derived stromal cells injec-
tion appeared to limit such collagen fibers remodeling,
as well as changes in the numbers of elastin fibers. In
contrast, we confirmed that scarring increased the fibro-
nectin content, which was unaffected by ASCs injection.
We measured laryngeal function in an original
manner, eschewing parallel plate rheometry. An electro-
dynamic shaker better evaluates vibratory tissue such
as the vocal fold. The procedure has undergone prelimi-
nary validation21 and seems to be reliable and reproduci-
ble. We found that vocal fold scarring decreased the first
resonant frequency and the stiffness (according to the
formula k 5x1
2
3 weight). Adipose-derived stromal cells
injection immediately after acute scarring limited these
decrease. After scarring, x1 decreased and lead to k
decrease as well. A reduction in stiffness caused by scar-
ring is the most common cause of vocal disturbance,28,29
probably due to the limitation of oscillations during pho-
nation. The stiffness decrease in soft tissues correlates
with a similar decrease in resistance to trauma such as
elastic deforming capacity. The histomorphometric anal-
yses performed, especially highlighting the decrease in
elastin fibres into lamina propria, helped us to under-
stand the mechanisms explaining biomechanical altera-
tions. Elastin fibers are the most important protein
involved in vocal fold vibration and resistance to
trauma. The observed decrease in elastin fibers might
then have affected vibration and probably modified the
first natural frequency. Because the biomechanical
shaker was tested on bone structures, and the rate of
change in the first natural frequency for the ADSC
treated samples was not significant as compared to the
nontreated scarred samples, this functional analysis
does not allow at this moment clear conclusions. Further
experimentations with a highest number of vocal folds
could allow us to definitively conclude.
The persistence of transplanted cells is controver-
sial. After 3 weeks, no GFP-positive ASCs were identi-
fied, and no GFP signal was detected from mesenchymal
or muscle cells. Our results differ from those of Kane-
maru et al.,1,2 Herteg€ard et al.,3 and Cedervall et al.4;
all reported that a transdifferentiation potential was evi-
dent in vivo. More recently, Svensson et al.22 and Hiwa-
tashi et al.14 failed to find any surviving injected cells 10
weeks and 1 month after transplantation, respectively,
and concluded that the observed improvements in vocal
fold healing was not solely attributable to any transdif-
ferentiation potential. It is possible that ASCs may dif-
ferentiate into different cell lineages, but ASCs may also
exert a predominantly paracrine-like effect. Various
approaches including fluorescence in situ hybridization,
the use of specifically labeled anti-human ASCs probes,
reverse transcription polymerase chain reaction, fluores-
cence in situ hybridization analysis, and the use of GFP
transgenic mice were used in the cited studies. In addi-
tion, the animals were sacrificed at different times (14–
70 days), and animal numbers were limited. The ques-
tion of ASCs persistence remains controversial and thus
additional studies are needed. Nevertheless, ASCs injec-
tion caused no observable side effects in our rabbit
model and appeared to be safe. All of the tissue samples
were histopathologically normal, and we found no sign
of dysplasia or anaplasia. Thus, ASCs injection may be
safe. However, malignancy would not arise within 6
weeks; therefore, long-term studies are required to prop-
erly explore this risk with ASCs injection. Most severe
vocal disturbances are attributable to chronic lesions
and scarring, but studies on the effects of ASCs in
chronic scarring models are not currently available. The
improvements observed in scarred ASCs-injected vocal
folds compared to saline-injected folds seemed rather
limited and may be not sufficient to improve human
vocal function. Combinations of cell therapy with bioma-
terials or growth factors may be necessary.30–33 Indeed,
according to Lianq et al.33 4 weeks after injury, no scar
formed in vocal folds treated with ASCs-micronized acel-
lular matrix (MADM) (dermal matrix) or ASCs. Eight
weeks after injury, vocal folds treated with MADM and
control vocal folds became atrophic and showed scarring,
and there were no obvious differences between them,
whereas vocal folds treated with ASCs- MADM or ASCs
were not atrophic and had a smoother surface.
CONCLUSION
Cell therapy using MSCs or (especially) ASCs
appears to be an effective method for treating vocal fold
scarring associated with severe vocal disturbance. We
found that injection of autologous ASCs improved vocal
fold wound healing, especially with regard to fibrosis,
inflammation, elasticity, and stiffness. Encouraging but
modest changes were noted in our model that limited
direct extrapolation to human for vocal fold function
recovery. Transplantation of ASCs offers promises but
still requires further investigation to achieve stronger
conclusion to further consider clinical applications.
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